Bispecific antibody is one of the important directions of tumor immunotherapy. Being the first-in-class bispecific antibody company in China,Wuhan YZY Biopharma Co., Ltd. has successfully built an internationally renowned bispecific antibody engineering and technology platforms,process program, production and quality management system,with perfect independent intellectual property rights. We independently developed a series of therapeutic bispecific antibody candidates with high clinical value and marketing value. We seek to carry out strategic collaborations with global pharmaceutical and biotech companies.
Platform collaborations：We have successfully developed series of safe and effective bispecific antibody candidates based on the YBODY® technology platform. To derive further value from the platform,we seek to drive co-development collaborations with innovative targets of bispecific antibody and monoclonal antibody, in the field of leukemia , Inflammation and cell therapy.
Product collaborations：We developed series of bispecific antibody candidates including M802（HER2/CD3）and M701 (EpCAM / CD3) which have successfully passed through the clinical approval work these are the first and second candidates about to enter the clinical trials,and 8 other candidates are in different preclinical stages before the clinical. We adopted business model by “domestic independent development, international equity transfer”, and willing to carry out collaborations in applying international clinical, transferring sales rights.